WHO approves emergency use of CanSino COVID vaccine

The World Health Organization (WHO) announced on Thursday the emergency approval of the Convidecia vaccine from the Chinese company CanSino Biologics.
The vaccine is given in a single dose and is recommended by the WHO for all age groups starting at age 18, according to a statement from the organization.
The vaccine that the company CanSIno Biologics developed — in partnership with the Institute of Biology of the Chinese Academy of Military Medical Sciences — is called Convidecia, but it is better known as Ad5-nCoV.

This substance is based on an adenovirus called Ad5, and therefore its name. It is a type of virus that under natural conditions causes respiratory diseases such as the common flu. But in this case, CanSino scientists modified that Ad5 to turn it into a vector that will carry a part of SARS-COV-2 inside the human body, to generate an immune response.
At first CanSino proposed a single dose scheme, but in August the same pharmaceutical company issued a statement in which it recommended in Mexico a second application of the vaccine six months after the first, to multiply the antibodies and offer greater protection.
CanSino joins the list of vaccines approved by the WHO with Pfizer-BioNTech, Moderna, Johnson & Johnson, AstraZeneca, Bharat Biotech, Novavax, Sinovac and Sinopharm.

In Mexico, the Federal Commission for the Protection against Sanitary Risks (Cofepris) authorized the Cansino vaccine for emergency use since February 2021.

I share with you that, at last, WHO approved the CANSINO vaccine against COVID-19 https://t.co/ycOUdWqng6
— Marcelo Ebrard C. (@m_ebrard) May 19, 2022

What we do at Animal Político requires professional journalists, teamwork, dialogue with readers and something very important: independence. You can help us keep going. Be part of the team.
Subscribe to Animal Político, receive benefits and support free journalism.#YoSoyAnimal

Original source in Spanish